Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vytorin First-Line Use Gains Traction, Schering Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Sales of Schering-Plough/Merck’s cholesterol-lowering therapies Zetia and Vytorin each exceeded $1 bil. in sales in 2005.

You may also be interested in...



Vytorin Beats Lipitor At LDL-Lowering In Data Analysis

A Merck/Schering-Plough-sponsored data analysis presented at the American College of Cardiology Scientific Sessions March 13 showed that more patients treated with Vytorin (ezetimibe/simvastatin) achieved lower levels of LDL cholesterol and apolipoprotein B compared to patients taking Pfizer's Lipitor (atorvastatin)

Vytorin Beats Lipitor At LDL-Lowering In Data Analysis

A Merck/Schering-Plough-sponsored data analysis presented at the American College of Cardiology Scientific Sessions March 13 showed that more patients treated with Vytorin (ezetimibe/simvastatin) achieved lower levels of LDL cholesterol and apolipoprotein B compared to patients taking Pfizer's Lipitor (atorvastatin)

Merck Unveils HDL-Cholesterol Drug Candidates

Phase III trials are starting for HDL-cholesterol therapy combining extended-release niacin and anti-flushing compound and for Zocor combination.

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel